Logo image of NANO.PA

NANOBIOTIX (NANO.PA) Stock Price, Quote, News and Overview

EPA:NANO - Euronext Paris - Matif - FR0011341205 - Common Stock - Currency: EUR

2.84  -0.02 (-0.7%)

NANO.PA Quote, Performance and Key Statistics

NANOBIOTIX

EPA:NANO (4/28/2025, 4:02:42 PM)

2.84

-0.02 (-0.7%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.97
52 Week Low2.62
Market Cap134.63M
Shares47.40M
Float39.99M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-20 2025-05-20
IPO10-29 2012-10-29


NANO.PA short term performance overview.The bars show the price performance of NANO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

NANO.PA long term performance overview.The bars show the price performance of NANO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40

The current stock price of NANO.PA is 2.84 EUR. In the past month the price decreased by -13.6%. In the past year, price decreased by -47.52%.

NANOBIOTIX / NANO Daily stock chart

NANO.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.36 293.65B
1ABBV.MI ABBVIE INC 16.92 266.76B
AMG.DE AMGEN INC 14.26 133.79B
GIS.DE GILEAD SCIENCES INC 13.47 114.50B
1GILD.MI GILEAD SCIENCES INC 22.33 112.99B
VX1.DE VERTEX PHARMACEUTICALS INC 1685.96 112.69B
ARGX.BR ARGENX SE 355.79 33.02B
22UA.DE BIONTECH SE-ADR N/A 22.12B
IDP.DE BIOGEN INC 7.16 15.20B
0QF.DE MODERNA INC N/A 9.34B
1MRNA.MI MODERNA INC N/A 9.08B
GLPG.AS GALAPAGOS NV N/A 1.56B

About NANO.PA

Company Profile

NANO logo image Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 108 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Company Info

NANOBIOTIX

60 rue de Wattignies

Paris ILE-DE-FRANCE FR

Employees: 110

Company Website: https://www.nanobiotix.com

Investor Relations: http://ir.nanobiotix.com

Phone: 33140260470

NANOBIOTIX / NANO.PA FAQ

What is the stock price of NANOBIOTIX today?

The current stock price of NANO.PA is 2.84 EUR. The price decreased by -0.7% in the last trading session.


What is the ticker symbol for NANOBIOTIX stock?

The exchange symbol of NANOBIOTIX is NANO and it is listed on the Euronext Paris - Matif exchange.


On which exchange is NANO.PA stock listed?

NANO.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for NANOBIOTIX stock?

11 analysts have analysed NANO.PA and the average price target is 11.24 EUR. This implies a price increase of 295.67% is expected in the next year compared to the current price of 2.84. Check the NANOBIOTIX stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NANOBIOTIX worth?

NANOBIOTIX (NANO.PA) has a market capitalization of 134.63M EUR. This makes NANO.PA a Micro Cap stock.


How many employees does NANOBIOTIX have?

NANOBIOTIX (NANO.PA) currently has 110 employees.


What are the support and resistance levels for NANOBIOTIX (NANO.PA) stock?

NANOBIOTIX (NANO.PA) has a resistance level at 3.01. Check the full technical report for a detailed analysis of NANO.PA support and resistance levels.


Is NANOBIOTIX (NANO.PA) expected to grow?

The Revenue of NANOBIOTIX (NANO.PA) is expected to decline by -3.32% in the next year. Check the estimates tab for more information on the NANO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NANOBIOTIX (NANO.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NANOBIOTIX (NANO.PA) stock pay dividends?

NANO.PA does not pay a dividend.


When does NANOBIOTIX (NANO.PA) report earnings?

NANOBIOTIX (NANO.PA) will report earnings on 2025-05-20.


What is the Price/Earnings (PE) ratio of NANOBIOTIX (NANO.PA)?

NANOBIOTIX (NANO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.44).


NANO.PA Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

NANO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA. NANO.PA has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NANO.PA Financial Highlights

Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -1.44. The EPS decreased by -33.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -101.06%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-250%
Sales Q2Q%-154%
EPS 1Y (TTM)-33.33%
Revenue 1Y (TTM)-138.62%

NANO.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to NANO.PA. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 33.28% and a revenue growth -3.32% for NANO.PA


Ownership
Inst Owners24.66%
Ins Owners0.3%
Short Float %N/A
Short RatioN/A
Analysts
Analysts85.45
Price Target11.24 (295.77%)
EPS Next Y33.28%
Revenue Next Year-3.32%